Evidence map›Paper›PMID 26378926›Full record

Trial reportPloS one2015

Long Term Development of Gut Microbiota Composition in Atopic Children: Impact of Probiotics.

N B M M Rutten, D M W Gorissen, A Eck, L E M Niers, A M Vlieger, I Besseling-van der Vaart, A E Budding, P H M Savelkoul, C K van der Ent, G T Rijkers

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Probiotics in infants for prevention of allergic disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. RETRACTED: Effect ofMicroorganisms · 2024
    Article
  7. Review
  8. Review
  9. TheMicroorganisms · 2022
    Review
  10. Article
  11. Effects of therapeutic probiotics on modulation of microRNAs.Cell communication and signaling : CCS · 2021
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. How Probiotics Affect the Microbiota.Frontiers in cellular and infection microbiology · 2019
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

N B M M RuttenDepartment of Pediatric Pulmonology and Allergology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, the Netherlands; Department of Pediatrics, St Antonius Hospital, Nieuwegein, the Netherlands.
D M W GorissenDepartment of Pediatric Pulmonology and Allergology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, the Netherlands.
A EckDepartment of Medical Microbiology and Infection Control, VU University Medical Centre, Amsterdam, the Netherlands.
L E M NiersDepartment of Pediatric Pulmonology and Allergology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, the Netherlands.
A M VliegerDepartment of Pediatrics, St Antonius Hospital, Nieuwegein, the Netherlands.
I Besseling-van der VaartWinclove Probiotics BV, Amsterdam, the Netherlands.
A E BuddingDepartment of Medical Microbiology and Infection Control, VU University Medical Centre, Amsterdam, the Netherlands.
P H M SavelkoulDepartment of Medical Microbiology and Infection Control, VU University Medical Centre, Amsterdam, the Netherlands; Department of Medical Microbiology, School of Nutrition & Translational Research in Metabolism (NUTRIM), Maastricht University Medical Centre, Maastricht, the Netherlands.
C K van der EntDepartment of Pediatric Pulmonology and Allergology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, the Netherlands.
G T RijkersDepartment of Sciences, University College Roosevelt Academy, Middelburg and Department of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, the Netherlands.
Amsterdam UMC Location VUmc · NLSt. Antonius Ziekenhuis · NLWilhelmina Children's Hospital · NLWinclove Probiotics (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImbalance of the human gut microbiota in early childhood is suggested as a risk factor for immune-mediated disorders such as allergies. With the objective to modulate the intestinal microbiota, probiotic supplementation during infancy has been used for prevention of allergic diseases in infants, with variable success. However, not much is known about the long-term consequences of neonatal use of probiotics on the microbiota composition. The aim of this study was to assess the composition and microbial diversity in stool samples of infants at high-risk for atopic disease, from birth onwards to six years of age, who were treated with probiotics or placebo during the first year of life.

methodsIn a double-blind, randomized, placebo-controlled trial, a probiotic mixture consisting of B. bifidum W23, B. lactis W52 and Lc. Lactis W58 (Ecologic® Panda) was administered to pregnant women during the last 6 weeks of pregnancy and to their offspring during the first year of life. During follow-up, faecal samples were collected from 99 children over a 6-year period with the following time points: first week, second week, first month, three months, first year, eighteen months, two years and six years. Bacterial profiling was performed by IS-pro. Differences in bacterial abundance and diversity were assessed by conventional statistics.

resultsThe presence of the supplemented probiotic strains in faecal samples was confirmed, and the probiotic strains had a higher abundance and prevalence in the probiotic group during supplementation. Only minor and short term differences in composition of microbiota were found between the probiotic and placebo group and between children with or without atopy. The diversity of Bacteroidetes was significantly higher after two weeks in the placebo group, and at the age of two years atopic children had a significantly higher Proteobacteria diversity (p < 0.05). Gut microbiota development continued between two and six years, whereby microbiota composition at phylum level evolved more and more towards an adult-like configuration.

conclusionPerinatal supplementation with Ecologic® Panda, to children at high-risk for atopic disease, had minor effects on gut microbiota composition during the supplementation period. No long lasting differences were identified. Regardless of intervention or atopic disease status, children had a shared microbiota development over time determined by age that continued to develop between two and six years.

Indexed as

Bacterial Typing TechniquesBifidobacteriumBiodiversityChildChild, PreschoolDietary SupplementsDouble-Blind MethodFemaleGastrointestinal MicrobiomeHumansHypersensitivityInfantInfant, NewbornLactobacillusMaleMetagenomePlacebosRNA, Ribosomal, 16SRNA, Ribosomal, 23S

Identifiers

PMID26378926
PMCPMC4574972
OpenAlexW2212092913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.